TauRX

Member

TauRx was founded in 2002 in Singapore, with primary research facilities and operation based in Aberdeen, UK. The company has dedicated the past two decades to developing treatments and diagnostics for Alzheimer’s and other neurodegenerative diseases due to tau protein aggregation pathology. Alzheimer’s disease is a leading cause of disability and death throughout the world and is one of the most important public health issues that need to be addressed globally. TauRx will contribute to addressing this unmet need with data from the completed Phase 3 LUCIDITY trial and pursuit of regulatory approvals in line with its overall plans to make hydromethylthionine mesylate (HMTM) available to patients and pursue clinical development in other related neurodegenerative diseases. For further information, please visit https://taurx.com/.